Canadian clinical guidelines for periodic eye examinations in children aged 0-5 years: Have we got it right? by McCulloch, Daphne L et al.
Canadian clinical guidelines for periodic eye examinations in 
children aged 0-5 years. Have we got it right?
KEY WORDS:
Children’s vision, vision screening, amblyopia, paediatric eye care, clinical 
practice guidelines, comprehensive eye examination, primary care, refrac-
tive error, strabismus
The clinical guidelines published simultaneously in the Canadian Journal 
of Ophthalmology and the Canadian Journal of Optometry aimed to pro-
vide clear evidenced-based guidelines for paediatric vision care that were 
agreed upon by the relevant professions and accepted Canada-wide. We 
read them with great interest. 
Briefly, the Joint Clinical Practice Guideline Expert Committee of the 
Canadian Association of Optometrists and the Canadian Ophthalmologi-
cal Society undertook a structured review of the evidence regarding early 
childhood vision care, to underpin guidelines for screening and examina-
tion of vision in Canada during the first 5 years of life. 
The new guidelines present Table 2 as a summary of current published guide-
lines for early vision care. However, the table is incomplete. The American Pub-
lic Health Association recommends a regular comprehensive eye examination 
(not a screening) at 6 months, 2 years and 4 years.1 American Optometric Associ-
ation (AOA) guidelines specify that low-risk/asymptomatic children have a first 
eye examination at 6-12 months of age, again at least once between 3-5 years, an-
other before grade 1 (approximately 6 years) and annually until 17 years;2 these 
are the bases for the Canadian Association of Optometrists’ guidelines.
The objectives of the new Canadian guidelines were to provide multidis-
ciplinary, evidence-based guidance on timings, intervals and types of ocu-
lar assessments for healthy children by reviewing studies on screening and 
examination techniques with outcomes of visual acuity, reduced amblyo-
pia, improved school performance and quality of life. The Committee se-
lected 16 key studies, which were graded as low or moderate quality. The 
key studies all focused on vision screening with an outcome of amblyopia 
rate. There seems to be little evidence available regarding other outcomes, 
including targeted school performance and quality of life. 
The lack of studies with high-quality evidence should not come as a sur-
prise; the best evidence, a prospective controlled clinical trial of full eye 
examinations versus a control group, would be unethical; the control group 
would be deprived of vision care. Thus, studies on various protocols, tim-
ings and outcome measures include ‘control’ groups that were tested ac-
cording to conventional practice. Nevertheless, the Committee concluded 
that there is strong evidence from well-conducted studies that children 
screened or examined early with regard to both ocular alignment and re-
fraction will have better visual acuity and lower rates of amblyopia. The 
Committee’s recommends that low-risk children should receive routine 
screenings by primary health care practitioners and an ocular assessment 
between 0 and 5 years, preferably prior to 3 years of age. They also state the 
importance of testing for amblyopia risk before 4 years, although this age 
contravenes the evidence that before 3 years is preferable. In their limita-
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tions section, the Committee states that implementation of the guideline for screening may be limited by available 
resources for vision screening (red reflex, cover tests and visual acuity) by primary care practitioners and there-
fore efforts should focus on access to oculovisual assessments. The Committee’s review excluded any discussion of 
higher-risk children; those with signs or symptoms, developmental delays, low socio-economic status, premature 
birth or familial risk factors. 
We were puzzled by the mixed message in the Canadian Committee’s conclusions, particularly regarding the expec-
tation that primary health care providers should manage vision assessment throughout the first 3 to 4 years of life, 
while acknowledging that such screenings are frequently incomplete. In 2017, the AOA Evidence-Based Optometry 
Guideline Development Group2 strongly recommended that“(i)nfants should receive an in-person comprehensive 
eye and vision assessment between 6 and 12 months of age for the prevention and/or early diagnosis and treatment 
of sight-threatening eye conditions and to evaluate visual development.” 
For this initial examination, the AOA finds reliable ‘Grade B’ clinical evidencea with benefits that outweigh costs; no 
harms were identified. Similar evidence is presented to support re-examination at least once between 3 and 5 years of 
age, and again before starting grade 1. These guidelines are not cited, although they are the most recent update by a mul-
tidisciplinary group that has screened nearly 1,500 publications and graded 241. To our knowledge, these are the only 
clinical guidelines based on a full systematic review that adhere to rigorous protocols for clinical guidelines; specifically,
“(c)linical practice guidelines are statements that include recommendations intended to optimize patient 
care that are informed by a systematic review of the evidence and an assessment of the benefits and 
harms of alternative care options.” 3It appears that the Canadian Committee has focused their atten-
tion on evidence of benefit without considering how to interpret a lack of evidence or evidence they 
omitted. Guidance should be optimal, particularly where the cost is not high and no harms of testing 
are identified. In addition to research evidence, consensus opinion, a valid level of evidence, indicates 
that a single eye examination in the first year of life will detect more disorders than screening. 
Health providers are likely to interpret ‘first exam before 36 months, or up to 48 months’ as a guideline for all chil-
dren, not as one that applies to only those in the lowest-risk group. In fact, visual risk factors in young children may 
not yet be identified. If we are to adopt this low standard of vision care for Canadian children, there is a serious onus 
to demonstrate that there is no harm to eliminating the current recommendation for full eye examinations before 
1 year of age. l
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FOOTNOTES
a. Clinical evidence quality is ranked from A to D. Grade B includes randomized clinical trials (RCTs) with weaker designs; cohort studies (retro-
spective or prospective); diagnostic studies; and case-control studies of diseases or conditions.
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